Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
Career and technical education programs are on the rise and appear poised for greater expansion. Well over half (61%) of educators report their districts have increased their CTE offerings over the ...
After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...
Researchers at Google have developed a new AI paradigm aimed at solving one of the biggest limitations in today’s large language models: their inability to learn or update their knowledge after ...
A majority of educators say their districts’ career and technical education offerings are increasing, driven in large part by growing student demand. That’s according to an EdWeek Research Center ...
Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...
The NFL season has been rife with tragedy—not that the league or its media partners have noticed. Cleveland Browns player Carl Nassib enters the bue tent during an NFL football game against the New ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...
Over the last two decades, career and technical education (CTE) has undergone significant reform and renewal, moving it from the margins to the center of education policy discussions. Long neglected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback